GSK Acquires IDRx for $1 Billion

Posted by ISPE Boston
On January 16, 2025

IDRx, a Boston-based, clinical-stage biopharm dedicated to developing precision therapeutics for the treatment of gastrointestinal stromal tumors (GIST) is being acquired by GSK. Under the agreement, GSK will pay $1 billion upfront, with potential for an additional $150 million success-based regulatory approval milestone payment. The acquisition includes lead molecule IDRX-42 being developed as a first- […]

Pharma 4.0: Navigating the Digital Shift

Posted by Colleen Sheehan
On January 14, 2025

Remember when digital transformation in pharma was still a new buzzword? Today, it’s the lifeline that’s modernizing how we bring medicines from lab to patient. Join our power-packed panel discussion on February 13th, 2025 at Tulip Interfaces in Somerville, MA where industry veterans will cut through the hype and show you what’s really working […]

CRISPR Pioneer Editas Medicine Pivots, Lays Off Staff

Posted by ISPE Boston
On January 9, 2025

Cambridge-based gene editing company Editas Medicine is planning a critical pivot to optimize its cost structure, extend its cash runway into Q2 2027, and position the company to accelerate its intent to achieve in vivo human proof of concept in approximately two years. “Recent scientific breakthroughs by the Editas team have convinced us that the timelines around […]

Neumora Therapeutics Antidepressant Stumbles in Clinical Trial

Posted by ISPE Boston
On January 9, 2025

Watertown-based Neumora Therapeutics, a clinical-stage biopharm with a pipeline consisting of seven clinical and pre-clinical brain disease programs, has announced disappointing results from a Phase 3 study of navacaprant for the treatment of major depressive disorder (MDD). The study did not demonstrate a statistically significant improvement in MDD study participants overall. “We are disappointed by […]

Chapter Member Anniversaries: January 2025

Posted by ISPE Boston
On January 3, 2025

Please congratulate the following members celebrating milestone anniversaries in January 2025. Their dedication to ISPE, the Boston Area Chapter and the industry is applauded! Over Twenty Years Dr. Anthony C. Bevilacqua, Ph.D., Mettler-Toledo Thornton Inc Beth M. Wescott, PE, Pfizer Brian L. Clark, GMP Operations Consulting Chris R. Mansur, Pioneer GMP Consulting Daniel E. Baxter, […]

Welcome New Members December 2024

Posted by ISPE Boston
On January 3, 2025

We would like to introduce the Members who joined ISPE in December 2024, welcome them to the Chapter, and encourage them (and all our members) to take advantage of the many professional development, networking and information resources available through ISPE. Fellow ISPE members are a terrific resource for help with everyday professional challenges. And the […]

Pharmaceutical Water Takes Center Stage in January

Posted by Brian Hagopian
On December 18, 2024

Pharmaceutical water will be the focus for the Boston Chapter’s first educational program of the 2025 year, being held the evening of January 16th at Alnylam’s Norton manufacturing facility. Pharmaceutical water is both a precious and widely used critical utility serving a multitude of purposes including acting as an ingredient, carrier, diluent, cleaning agent, and […]

A Holiday Poem for ISPE Boston!

Posted by Jesse McLaughlin
On December 17, 2024

‘Twas the night before Christmas, in ISPE’s domain, Not a piece of equipment was out of its lane. The SOPs were placed by the systems with care, In hopes that St. Nicholas soon would be there. The members of ISPE, in their dreams so deep, While visions of compliance did peacefully sleep. And I in […]

ISPE Boston Board’s Strategic Planning

Posted by Jesse McLaughlin
On December 9, 2024

Introduction On Thursday, November 21, we, the ISPE Boston board, met in person to establish the framework for a rolling 3-year Chapter strategy. Our need for a new strategy framework is driven by the growth of our Chapter and the significant investment in the New England health sciences sector. At the same time, we are […]

Sarepta Acquires RNA Drugs for $500 Million

Posted by ISPE Boston
On December 5, 2024

Sarepta Therapeutics has inked an exclusive licensing and collaboration agreement with Arrowhead Pharmaceuticals under which Sarepta will obtain exclusive global rights to multiple clinical, preclinical, and discovery-stage programs for rare, genetic diseases of the muscle, central nervous system (CNS), and lungs. The agreement will add meaningfully to Sarepta’s mid- and early-stage pipeline, complementing the Company’s existing leadership in […]

Page 5 of 118«‹3 456 7 ›»